Ind-Swift Laboratories Q1 FY27: PAT 2.04x, EBITDA 17.91%

Strong start to FY27 for Ind-Swift Laboratories

Ind-Swift Laboratories reported a sharp improvement in profitability for the April to June 2026 quarter (Q1 FY27), supported by higher sales and margin expansion. On a standalone basis, profit after tax (PAT) excluding exceptional items rose 2.04 times year-on-year to ₹24.68 crore, compared with ₹8.12 crore in Q1 FY26. Operating EBITDA also climbed sharply, rising 2.85 times year-on-year to ₹33.32 crore from ₹8.66 crore. Operating income increased to ₹186.08 crore in Q1 FY27 from ₹153.58 crore a year earlier. The company linked the operating improvement to a better business mix and expansion in margins.

Standalone revenue growth and profitability jump

Standalone revenue from operations for Q1 FY27 stood at ₹186.08 crore, up 21.16% year-on-year from ₹153.58 crore. The company’s standalone operating EBITDA for the quarter was ₹33.32 crore, compared with ₹8.66 crore in Q1 FY26. This step-up in operating profit translated into a higher operating EBITDA margin of 17.91%, up from 5.33%, an improvement of 1,258 basis points. PAT margin also strengthened sharply to 13.26% from 4.99%, improving by 827 basis points.

The company also disclosed additional standalone profit line items in its results communication. Total income including other income rose to ₹193.71 crore from ₹162.58 crore. Profit before exceptional items and tax was reported at ₹32.66 crore. After exceptional items of ₹0.24 crore and total tax expense of ₹7.98 crore, standalone PAT was ₹24.44 crore. Basic and diluted EPS was ₹2.81 versus ₹1.18 a year earlier.

What drove the margin expansion

The quarter was marked by a clear uplift in operating leverage, with the EBITDA margin nearly tripling year-on-year to 17.91%. Ind-Swift Laboratories attributed the operating performance to improved efficiencies and a better business mix. The results commentary also described a shift in positioning, highlighting a transformation from an API player to a focused finished dosage formulation (FDF) manufacturer. While the release did not quantify segment-level contributions, the margin and profit changes were large enough to indicate a materially different earnings profile versus the year-ago quarter.

Consolidated numbers show higher sales and profit

On a consolidated basis, Ind-Swift Laboratories reported net sales of ₹191.45 crore in Q1 FY27, compared with ₹152.00 crore in Q1 FY26, a rise of 25.35% year-on-year. Consolidated adjusted net profit was ₹24.86 crore, up 183.5% year-on-year and 28.9% quarter-on-quarter. The company also reported consolidated profit before tax (PBT) of ₹32.56 crore, up 214.3% year-on-year and 172.2% quarter-on-quarter.

Cost disclosures on the consolidated side showed total expenses of ₹165.60 crore, up 6.3% year-on-year and 5.3% quarter-on-quarter. Raw material consumption increased 25.0% year-on-year to ₹81.76 crore, while employee expenses rose 21.6% year-on-year to ₹39.56 crore. Interest costs declined 38.3% year-on-year to ₹0.71 crore. Depreciation and amortisation rose 13.5% year-on-year to ₹7.58 crore. Other income declined 47.5% year-on-year to ₹7.65 crore but increased 244.6% quarter-on-quarter.

Board approval, auditors’ limited review, and land monetisation

The company informed exchanges that its Board of Directors approved the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026 on August 10, 2026. The approval also covered the limited review reports from statutory auditors Rattan Kaur & Associates.

Separately, the company disclosed that its board approved the sale of surplus land for ₹17.50 crore. The disclosure did not provide additional execution timelines in the text provided, but it was referenced alongside the Q1 results communication.

Earnings call audio released; transcript pending

Ind-Swift Laboratories released the audio recording of its Q1 FY27 earnings call on August 17, 2026. The call addressed the financial performance for the quarter ended June 30, 2026. The company said the audio file is available on its investor relations page under Regulation 46 disclosures. It also said the transcript is pending upload to the company website and exchange portals, and that the full transcript will be shared with the Bombay Stock Exchange and the National Stock Exchange of India Limited and uploaded to its website in due course.

Stock market reaction and investor focus

Following the results, Ind-Swift Laboratories surged 18.19% to ₹280.40, reflecting investor attention on the sharp improvement in profitability and margins. Another market update referenced a consolidated results snapshot with a CMP of ₹237.24 (+3.87%). These price points were reported in different market notes around the same results period.

Key reported metrics at a glance

Consolidated cost highlights disclosed for Q1 FY27

What investors may track next

With the earnings call audio already available, the next disclosure to watch is the publication of the full transcript on the company’s website and on exchange portals, as indicated by the company. Investors may also track follow-through on the planned surplus land sale of ₹17.50 crore, which was approved by the board alongside the quarterly results. The quarter ended June 30, 2026 sets the initial financial tone for FY27, and upcoming filings and commentary are likely to add more detail on business mix and drivers of margin expansion.

Conclusion

Ind-Swift Laboratories began FY27 with strong growth in revenue and a steep improvement in profitability, led by a sharp jump in operating EBITDA and a higher margin profile. The company has also moved to improve investor access to information by releasing its earnings call audio and indicating that the transcript will be shared with BSE, NSE, and uploaded to its website in due course.